The Hidden Gap
in Market Access
A therapy can achieve regulatory approval, secure reimbursement, and gain guideline backing. Yet, it still fails to reach patients because execution fractures across the clinical decision pathway.
Real-world data effectively tracks prescriptions, treatment volumes, and market share, but it consistently misses the core driver: the clinical reasoning behind those numbers.
Approvals Don't Treat Patients
Execution Does
Before a decision is formalized:
-
Patients are not identified
-
Required tests are not completed
-
Eligible patients fail to enter treatment pathways
Following a treatment decision:
-
Treatment initiation is delayed
-
Therapy is interrupted or discontinued
Ultimately, these execution breakdowns create substantial patient access barriers and measurable leakage across the care pathway.
Traditional RWD Explains Market Performance
Decision Intelligence Explains Why Markets Perform the Way They Do
Medigator is an AI-powered platform for continuously supporting and tracking complex clinical treatment decisions.
By supporting specialty drug treatment decisions at the point of care, we create a secure clinical decision observation window called Medigator Insights.
This enables pharma companies to access native EHR-derived decision analysis and understand how clinical decisions around specialty drug treatment shape market performance.
Unlike traditional RWD, Medigator Insights does more than show what was prescribed. It reveals:
-
Why eligible patients were lost
-
Where access breaks down
-
How treatment decisions change across real-world clinical settings
-
Which barriers prevent therapy adoption and continuation
This enables pharma companies to:
-
Quantify missed patients
-
Identify revenue leakage
-
Locate the clinical barriers that limit market growth
Decision
Fidelity
Preserve clinical decision pathways with granular decision-level fidelity
Reasoning
Traceability
Deconstruct the clinical judgment, testing status, eligibility criteria, and treatment logic behind each decision
Real-Time
Visibility
Reflect real-time clinical activity
instead of delayed retrospective data
Deconstruct Clinical Decisions to Reveal Market Opportunities
Addressable Patient Population
Uncover the true market baseline
and total addressable population
-
Segment patients by stage, pathology, and care setting to define population structure
-
Map real-world patient distribution to reveal the treatment gap across diagnosed cohorts
-
Surface untreated and under-recognized groups to expand the addressable market
Molecular Testing Readiness
Understand entry readiness into
treatment pathways
-
Assess the completeness of diagnostic and molecular testing required before therapy initiation
-
Validate timing and sequencing of testing against clinical pathways
-
Locate clinical breakdowns that delay or prevent treatment initiation
Eligibility & Guideline Gap
Quantify missed eligible patients
and unmet opportunities
-
Match patient profiles against guideline-defined eligibility criteria
-
Identify cases where eligible patients do not proceed to treatment
-
Measure the volume and distribution of missed opportunities
Treatment Decision & Behavior
Understand treatment selection
to reveal adoption drivers
-
Trace how eligible cohorts transition to specific lines of therapy
-
Expose where real-world treatment decisions diverge from guideline recommendations
-
Extract key factors associated with therapy selection across contexts
Execution & Persistence
Measure treatment initiation
and continuity
-
Confirm whether selected therapies are initiated in real-world settings
-
Monitor adherence, persistence, and switching across treatment lines
-
Detect where and when discontinuation occurs along the care journey
Market Outcome & Access Dynamics
Connect decisions to real-world
market performance
-
Aggregate treatment activity into measurable market volume and share
-
Compare performance across access conditions and reimbursement environments
-
Link observed patterns to revenue impact and growth potential
Traditional RWD provides outcome-level analysis, showing which treatments patients received, whether they switched or discontinued treatment, and what outcomes followed.
Medigator Insights provides decision-level analysis, examining the testing requirements, eligibility criteria, treatment considerations, initiation decisions, and access barriers behind those outcomes. This pinpoints where and why eligible patients fail to progress to treatment.
Pharmaceutical companies can access only approved analytical outputs. They do not receive raw patient-level clinical records, and the permitted scope is defined by institutional approvals and formal data-use agreements.
No. Neither individual patients nor physicians can be identified from the information provided to pharmaceutical companies. Cell suppression, role-based access, encryption, and restrictions against re-identification are applied to protect confidentiality.
For Pharmaceutical or Life Sciences Companies
-
Paid enterprise plans: Data analytics and customization services
-